Form 8-K - Current report:
SEC Accession No. 0001493152-23-004481
Filing Date
2023-02-13
Accepted
2023-02-13 16:05:44
Documents
16
Period of Report
2023-02-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 49276
2 ex5-1.htm EX-5.1 17793
3 ex10-1.htm EX-10.1 242519
4 ex99-1.htm EX-99.1 13442
5 ex5-1_001.jpg GRAPHIC 3536
  Complete submission text file 0001493152-23-004481.txt   562213

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE pcsa-20230209.xsd EX-101.SCH 3245
7 XBRL LABEL FILE pcsa-20230209_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE pcsa-20230209_pre.xml EX-101.PRE 22371
10 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3607
Mailing Address 7380 COCA COLA DRIVE SUITE 106 HANOVER MD 21076
Business Address 7380 COCA COLA DRIVE SUITE 106 HANOVER MD 21076 443-776-3133
Processa Pharmaceuticals, Inc. (Filer) CIK: 0001533743 (see all company filings)

IRS No.: 451539785 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39531 | Film No.: 23618321
SIC: 2834 Pharmaceutical Preparations